- Daiichi Sankyo‘s operating income for the first quarter reached 96.71 billion yen, a 4% increase year over year, surpassing the estimated 81.76 billion yen.
- Net income increased marginally by 0.1% to 85.50 billion yen, beating the forecasted 69.55 billion yen.
- Net sales rose by 8.8% to 474.60 billion yen, exceeding the estimated 463.99 billion yen.
- The company maintains its 2026 yearly forecast for operating income at 350.00 billion yen, despite the estimate being higher at 366.07 billion yen.
- Daiichi Sankyo continues to forecast net income at 300.00 billion yen, with external estimates slightly higher at 309.33 billion yen.
- The company projects net sales of 2.00 trillion yen for 2026, compared to a higher estimate of 2.04 trillion yen.
- Expected dividend remains at 78.00 yen, which is slightly above the estimated 77.74 yen.
- In market activity, shares rose by 3.8% to 3,790 yen with 3.1 million shares traded.
- Analyst recommendations include 19 buys, with no holds or sells noted.
Daiichi Sankyo on Smartkarma
Analyst coverage of Daiichi Sankyo on Smartkarma has been positive, with insights from top independent analysts like Tina Banerjee and Akshat Shah. Tina Banerjee highlighted Daiichi Sankyo‘s FDA approval for Datroway for certain types of NSCLC, leading to potential milestone payments and revenue growth expectations for FY26. Additionally, Tina Banerjee reported on the strong FY25 results of Daiichi Sankyo, driven by Enhertu, with a promising outlook for FY26 and the announcement of a substantial ¥200B buyback plan.
Akshat Shah discussed Mizuho Bank’s intention to raise US$151m by selling part of its stake in Daiichi Sankyo, analyzing the deal’s implications within the ECM framework. The overall sentiment from the analyst coverage leans bullish, indicating optimism towards Daiichi Sankyo‘s performance and strategic moves in the market. These insights provide valuable information for investors considering the pharmaceutical company’s future prospects and investment opportunities.
A look at Daiichi Sankyo Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts reviewing Daiichi Sankyo‘s long-term outlook have identified promising factors that could bode well for the company’s future performance. With a strong growth score of 5, Daiichi Sankyo is projected to experience significant expansion opportunities in the coming years, reflecting positively on its market potential. Additionally, the company’s resilience score of 4 indicates a solid ability to withstand market fluctuations and challenges, bolstering its stability and sustainability over time.
While Daiichi Sankyo‘s value and dividend scores are more moderate at 2, its momentum score of 3 suggests a steady upward trajectory in terms of market interest and investor sentiment. This combination of growth potential, resilience, and momentum positions Daiichi Sankyo favorably for long-term success amid the competitive pharmaceutical industry landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
